Syncell Inc’s Post

My mission, to build a stellar technology by empowering the best and learn from the brightest. With a degree in Physics, a slight paraphrase of the famous quote by Sir Isac Newton fits well here: you see further “by standing on the shoulders of giants”

If you survived the toughest downturn in biotech history: Congratulations on a job well done.   But as we turn to 2025, the job will only get tougher for CEOs and boards. You don’t have the luxury of time. You must deliver again, even in uncertain markets.   Join BioCentury, BIA, and special guests for our second annual CEO and investor dialogue on the sidelines of the Jefferies London Healthcare Conference - Biotech's Next Challenge: Delivering the Story. Learn more and register: https://loom.ly/vIIBprM #drugdevelopment #investors #AI #pipelines

Happy to share that my company, Lightcast, is getting the spotlight treatment. Check out this new profile of our technology from Illumina Ventures to find out how we’re enabling the precise interrogation of single cell interactions and functional behaviours at scale.   #drugdiscovery #antibodydiscovery #cellandgenetherapy #singlecellanalysis #biotechnology #microfluidics

𝗚𝗿𝗲𝗮𝘁 𝘁𝗼 𝗯𝗲 𝗼𝘂𝘁 𝗮𝗻𝗱 𝗮𝗯𝗼𝘂𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗶𝘁𝘆 𝘁𝗵𝗶𝘀 𝗺𝗼𝗿𝗻𝗶𝗻𝗴 There's nothing better than face to face meetings. Loving this city a lot so far... Here's a few takeaways... - Cell & Gene is an attractive buy right now and we are seeing huge amount of demand for capable leaders who can transform existing or future assets. - There's currently a considerable wave of demand to replace across CEO, CCO & CFO positions. - We're seeing increased activity for traditionally North American PE firms now exploring Europe. #PEInsights #NY #LifeSciences #ExecutiveSearch

If you are attending #AIChE2024, don’t miss this workshop and panel discussion on Democratizing Modeling, Simulation and Computational Data Sciences! 

UBS recently held its second life sciences conference, tackling critical trends in the biotech industry. Panelists, including Tim Haines (Abingworth) and Jasper Bos (Forbion), discussed the profound effects of collaboration between biotech and big pharma, biotech's variable performance in public markets, and the rising impact of AI in drug discovery. As VC investors become more intertwined with pharma, real estate is emerging as a key sector to watch, especially when it comes to facilities supporting lab work and AI capabilities. https://lnkd.in/ek2Cx4xG #lifesciences

"Charles River’s work with Ori is part of a larger commitment to improve and scale advanced therapies through the adoption of cutting-edge closed and automated platforms to meet the growing patient demand for life-saving therapies. The test of Ori’s new IRO platform using head-to-head process transfer runs shows promising results and provides therapeutic developers another option for manufacturing and helps to address the manufacturing bottleneck challenge.” - Matthew Hewitt, Vice President, CTO Manufacturing Business Division at Charles River Laboratories We recently presented new data from our ongoing collaboration with Charles River Laboratories, where Jason C. Foster highlighted IRO®’s ability to reduce cost of goods by up to 50% and cut production time by up to 25%. When compared to a legacy manufacturing technology, IRO not only delivered higher CAR+ cell yields in less time, but also streamlined workflows and enhanced biological performance – all of which were demonstrated live at our 'Experience IRO' event in Boston. By Automating Better Biology™, the IRO platform empowers therapy developers to scale their impact with efficient, standardized manufacturing processes. A huge thank you to the team at Charles River and to everyone who joined us in Boston. If you missed out, don’t worry – schedule your 1:1 demo to see IRO in action ➡️ https://lnkd.in/eXEXEGZZ Read more about our collaboration ➡️ https://lnkd.in/e5gT-zXz #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

🎤 It was fantastic to see Michael C. representing Cellino at Benchtalk 2024! He delivered a compelling presentation on **“Adaptive Biomanufacturing to Scale Autologous Cell Therapy”**, sharing insights from top labs on achieving end-to-end automation. 💡 Michael discussed innovative strategies to tackle key challenges in automation, connectivity, and data accessibility – all critical components for the future of biomanufacturing. His expertise and passion for advancing lab automation truly shined through. 🌟 If you’re looking to explore automation best practices or have questions about Cellino's approach, don’t hesitate to reach out! #Benchtalk2024 #CellinoBio #LabAutomation #Biomanufacturing #EndToEndAutomation #ScientificDiscovery

Interesting! Illumina celebrates the GRAIL divestment by buying Fluent BioSciences Inc. - maker of a single-cell analysis product. Notes: - yay multiomics! - workflow is Fluent sample prep -> NGS -> Fluent software - fits with recent ilmn cfo comment on the importance of NGS as multiomics “readout” - Was an Illumina Ventures investment which isn’t a great antitrust look - press release carefully quotes Steven Barnard noting the illumina is committed to supporting an open “ecosystem” of omics providers - seems to be a direct competitor to 10x Chromium Single Cell - Fluent had previously announced Ultima Genomics as a partner (ouch 😬) - Illumina press release wording implies deal already closed implying that there is no automatic HSR antitrust review delay which also implies price was <$120M. Anyway, my congrats to both companies and best of luck! 👏👏👏

As we commemorate the 10-year milestone of #QuantSeq, Lexogen's flagship product, we've had the privilege of sitting down with some of the brilliant minds who work tirelessly with #QuantSeq every day. Here's an excerpt from our interview with Filippo Passardi, our dedicated Product Manager: "At the core of our mission is ensuring the success of our customers. We recognize that their success is our success. QuantSeq has been a presence in the market for a significant period. When I took on the role, QuantSeq had already been available for 8 years. The challenge I embraced was reinventing its presentation. I asked myself, 'How can I, as a Product Manager, tailor QuantSeq to scientists' current needs, and at the same time explain the technology in a simpler way to NGS newcomers?' The result? We successfully broadened our audience. QuantSeq, much like a growing child, has undergone continuous improvements despite its unchanging technology. It has adapted to the evolving landscape of NGS sciences, a field that progresses rapidly. Now, QuantSeq stands as a trusted, robust, and established product— and even improved through a decade of refinement by Lexogen scientists. We've explored every conceivable combination, accumulating an extensive publication history with this product." → Meet Filippo Passardi, a Product Manager at Lexogen, responsible for QuantSeq in his portfolio. With two years of experience in product management and an impressive 15-year background as a sales representative, Filippo brings a wealth of expertise to the table. Explore more about our QuantSeq Family of products https://lnkd.in/darhvshS , and feel free to reach out if you have any questions. We're here to help! #rnaseq #TheRNAExperts